From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics – placing and “retail offer”… and CEO Stuart Ashman talking absolute rubbish, shares still a BUY

By Tom Winnifrith & Steve Moore | Tuesday 21 November 2023

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

SkinBioTherapeutics (SBTX) has announced a placing and “retail offer” at 19p per share to raise, respectively, a minimum of £3 million and up to £0.25 million, with CEO Stuart Ashman stating this is needed “to help with the current commercialisation and development strategy of AxisBiotix in skin health, with our latest venture beginning in acne, as well as providing a stronger financial base to support our strategic partnering discussions around three of our other business pillars. The funding will also support us with working capital and strengthen our balance sheet”. Tom Winnifrith has applied for shares in the offer and we suggest you do too BUT Ashman is talking bollocks and we will be slashing our target price from 150p.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 16:52:13